Annual results for 2012: significant advance for four drug candidates and strong cash position

• Three clinical trials initiated with anti-KIR antibody lirilumab (IPH2102/BMS-986015), including a Phase II trial
• IPH2201/NN8765 Phase I clinical trial enrolling patients
• IPH33 drug candidate selected and ready for partnering  
• IPH41 drug candidate selection expected by yearend
• Higher revenue, lower expenditures and lower losses versus 2011
• Strong cash position (32.6 million euros) with horizon to mid-2015

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, reports today its consolidated financial results for the year ended December 31, 2012. The consolidated financial statements are attached to this press release.

Conference call replay will be available until June 5, 2013:
Dial in number: +33 (0)1 72 00 15 00 Access number: 280550#
On line version :  http://sharing.arkadin.com/pvosbhgabf
Password : Arkadin2013